Market Research Reports, Inc.

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success, New Report Launched

Market Research Reports, Inc. has announced the addition of “Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success” research report to their website http://www.MarketResearchReports.com

 

Lewes, DE -- (SBWIRE) -- 03/03/2015 -- All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need. While large pharma companies are active in M&A deals, the Mature biotech companies are sticking to its core expertise and venturing into unexplored/new therapy; e.g., GILD in anti-cancer and BIIB for hemophilia.

Alike small molecule generics, biosimilar will also get easier and getting similar pace of recognition in coming years; where AMGN, BIIB already started investing in this space and can emerge as a big player in coming years.

REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years.

GILD has announced the dividend payment and now all eyes will be on CELG and BIIB

Spanning over 90 pages "Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success" report covering Key Pipeline Drugs, Alexion Pharma – Pipeline Maturity will witness a Strong 2015 for ALXN, Amgen – Focus On New Biologics For Larger Market And Exploiting Biologics' Manufacturing Experience For Biosimilars Gain, Biogen Idec – Growth from Newly Launched Products + Clinical Milestones of Novel Pipeline, Celgene – Innovative Strategies for Long Term Gains, Gilead Sciences – Poised to Emerge as a Leader in HCV Treatment, Regeneron – Late-Stage Pipeline Potential – Accelerator for Further Growth, Vertex Pharma – From Large Volume Market to Niche Indications – Transformation has Paid. This report Covered These Companies - Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron, Vertex, ACOR, ALXN, AMGN, BIIB, CELG, GILD, REGN, VRTX.

For further information on this report, please visit- http://www.marketresearchreports.com/mp-advisors/mature-biotech-outlook-2015-new-therapy-ventures-pave-way-success

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at:
http://www.marketresearchreports.com/subscribe-to-newsletter